Ποια είναι η τιμή για Corvus Pharmaceuticals, Inc. (CRVS)

Η τιμή για Corvus Pharmaceuticals, Inc. (CRVS) είναι $14.07

Ποια είναι η κεφαλαιοποίηση αγοράς για Corvus Pharmaceuticals, Inc. (CRVS)

Η κεφαλαιοποίηση αγοράς για Corvus Pharmaceuticals, Inc. (CRVS) είναι $1.18B

Corvus Pharmaceuticals, Inc. (CRVS) Τιμή και Κεφαλαιοποίηση Αγοράς

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

Η τιμή για CRVS	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$62,597.72 $1.18B	NVDA	$5.264T	+444,783.12%
$55,907.40 $1.18B	AAPL	$4.701T	+397,234.89%
$49,674.85 $1.18B	GOOG	$4.177T	+352,940.00%
$45,396.40 $1.18B	MSFT	$3.817T	+322,532.97%
$34,086.37 $1.18B	AMZN	$2.866T	+242,152.45%

Η τιμή για CRVS

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$62,597.72 $1.18B